EASD 2019 — Semaglutide improves glycemic control and BMI better than liraglutide in T2D


  • Brandon May
  • Conference Reports
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • Semaglutide, a glucagon-like peptide-1 analogue, was associated with better glycemic control and greater reductions in body weight compared with liraglutide in adult patients with type 2 diabetes (T2D).

Why this matters

  • Patients with T2D have difficulty achieving optimal control of blood glucose if they are also overweight or obese.

Study design

  • Adults with T2D who were taking 1-3 oral glucose-lowering drugs were randomly assigned:
    • Once-weekly semaglutide 1.0 mg (n=290).
    • Once-daily liraglutide 1.2 mg (n=287).
  • Change in HbA1c from baseline to week 30 comprised the primary efficacy endpoint.
  • Confirmatory secondary endpoint was change in body weight at week 30.
  • Funding: Novo Nordisk.

Key results

  • Compared with mean baseline HbA1c (8.2%), treatment with semaglutide was associated with a greater percentage-point reduction in HbA1c by week 30 vs liraglutide (1.7%-point change vs 1.0%-point change; estimated treatment difference [ETD], −0.69% point; 95% CI, −0.82 to −0.56; P<.0001>
  • A greater proportion of semaglutide-treated patients achieved HbA1c
  • More patients in the semaglutide arm also achieved weight loss of ≥5% (55.9% vs 17.7%; OR, 5.89; P<.0001 and vs or p>
  • Slightly more adverse events were observed in the semaglutide group (70.6% vs 66.2%).

Limitations

  • Lack of participant lifestyle data.